Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for recurrent or progressive primary central nervous system lymphoma
NL-OMON47301Phase 2Withdrawn
- Sponsor
- University of Vienna
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in primary central nervous system lymphoma (PCNSL), sponsored by University of Vienna. Primary endpoints: Overall response rate and Safety. Planned start Jan 2019; status: withdrawn.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NL-OMON47301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47301.